Dicloced

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dicloced

Quick Facts

Property Description
Active Ingredient Diclofenac (Sodium/Potassium)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Origin Synthetic derivative (Phenylacetic acid)
Primary Action Inhibits prostaglandin synthesis (COX inhibitor)
Available Forms Oral tablet, capsule, topical gel, ophthalmic solution

Classification and Origin: What Type of Medicine is Dicloced?

Dicloced is a pharmaceutical preparation fundamentally defined by its active ingredient, Diclofenac, and its classification as a Nonsteroidal Anti-inflammatory Drug (NSAID). This drug belongs to a class of synthesized compounds used for their general analgesic and anti-inflammatory properties, a use that is clinically recognized globally. Structurally, Diclofenac is recognized as a derivative of phenylacetic acid, confirming its synthetic origin. The medicine functions primarily as an inhibitor of the Cyclooxygenase (COX) enzymes, a mechanism central to its efficacy. This mechanism helps ease discomfort by targeting the pathway responsible for tissue inflammation.

Diclofenac Composition and Physical Forms

The essential active ingredient in Dicloced is Diclofenac, typically available as the sodium or potassium salt. Dicloced products are generally prepared as a single active component and are available in a range of formulations for diverse routes of administration, allowing for both systemic and local relief. These preparations include various oral tablets (such as delayed or extended-release forms) and capsules intended for systemic absorption. For local action, Diclofenac is also formulated into topical gels and ophthalmic solutions (eye drops), which employ specialized excipients to facilitate targeted delivery to the affected area.

General Therapeutic Purpose and Benefit

The general therapeutic purpose of a Diclofenac product is to provide relief by mitigating the body's pain and inflammatory response. By acting as a COX inhibitor, the medicine blocks the synthesis of prostaglandins, which are chemical mediators responsible for sensitizing nerve endings and initiating inflammation. The substance’s analgesic properties contribute to reducing acute pain intensity across various scenarios. This confirms the medicine's fundamental benefit in mitigating general discomfort, swelling, and stiffness by reducing these inflammatory chemical signals.

Regulatory References

  1. StatPearls, NIH

What side effects are possible with Dicloced?

Possible Side Effects and Safety Information

The safety characteristics of Dicloced, which contains the Nonsteroidal Anti-inflammatory Drug (NSAID) Diclofenac, are documented by regulatory agencies and organized by the type and frequency of the adverse reaction.


Key Adverse Reaction Categories

Official labeling classifies adverse events primarily by the physiological system affected. Common reactions often involve Gastrointestinal Disorders, such as nausea, abdominal pain, flatulence, and diarrhea. Other frequently listed reactions include headache and dizziness. Rarer but serious adverse reactions are prominently documented across different systems.


Serious Adverse Reactions

Regulatory documents emphasize the potential for serious, life-threatening events. These include Serious Cardiovascular Thrombotic Events (such as myocardial infarction and stroke), which may increase with higher doses and longer duration of exposure. The risk of Serious Gastrointestinal Events (inflammation, bleeding, ulceration, and perforation) is also noted, which can occur at any time during treatment, often without warning symptoms. Severe, sometimes fatal, skin reactions (like Stevens-Johnson Syndrome) and anaphylactic reactions are also documented.


Population-Specific Safety Considerations and Limitations

Safety statements include specific considerations for certain groups. Older adults are generally at a higher risk for serious gastrointestinal adverse events. Use is generally restricted in patients with established congestive heart failure (NYHA Class II-IV) or in the setting of Coronary Artery Bypass Graft (CABG) surgery. Furthermore, use is generally avoided during the last trimester of pregnancy due to the risk of premature closure of the fetal ductus arteriosus.

Overdose and Emergency Response

Overdose and when to seek help

The following information details the officially documented overdose profile for Dicloced (Diclofenac), strictly based on government regulatory documentation.

Feature Regulatory Statement
Documented overdose presentations May be asymptomatic or exhibit minor, self-limiting gastrointestinal symptoms (e.g., nausea, vomiting, stomach pain).
Physiological systems affected Gastrointestinal, Central Nervous System, Renal, and Cardiovascular systems.
Dose-related factors Severe or massive ingestions are associated with a greater risk of life-threatening events.
Population-specific notes Elderly patients have an officially noted greater risk for serious gastrointestinal events in overdose situations.
Emergency-response statements Seek medical help right away. Call your local emergency number or contact the Poison Help hotline.
When immediate help is required Urgent attention is required for signs of severe toxicity, including chest pain, shortness of breath, weakness, or slurred speech.

Classification Regulatory Statement
Severity classification Ranges from asymptomatic to severe/life-threatening manifestations (seizures, coma, acute renal failure).
Overdose-context constraints Management is defined by symptomatic and supportive treatment. No specific antidote is known.

Official Overdose Statements

  • Acute overdose frequently presents with non-specific symptoms such as drowsiness, dizziness, headache, and tinnitus (ringing in the ears).
  • Severe toxicity may involve officially documented outcomes including gastrointestinal bleeding, acute renal failure, seizures, and hypotension.
  • Management procedures listed in regulatory documents include the potential use of activated charcoal, gastric lavage, IV fluids, and continuous monitoring of vital signs and ECG.

Connection to the overall overdose profile:

The regulatory documentation defines the overdose profile through a dual classification of presentation, ranging from mild, non-specific symptoms to documented life-threatening events. This structure mandates that emergency medical care be sought immediately upon suspected overdose, as treatment relies solely on regulator-described symptomatic and supportive measures due to the official lack of a specific antidote.

Therapeutic Uses of Dicloced

What Dicloced Treats: Main Uses and Benefits

This medication is primarily used for managing symptoms related to physical discomfort and pain arising from various sources, including acute pain and discomfort from long-term inflammatory conditions. It is applied in clinical settings where supportive symptom management is appropriate for conditions involving heightened symptoms. The medication is commonly used to help with conditions characterized by periods of heightened symptoms, such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and various forms of acute musculoskeletal pain.

It helps manage the cluster of symptoms associated with inflammatory or irritative states, such as localized swelling and tenderness. By easing these manifestations, the medication offers supportive relief that helps maintain a sense of stability when symptoms are more noticeable. It is relevant for easing painful manifestations, assisting with maintaining functional stability, and supporting patients during episodes of heightened discomfort.

“This approach is relevant when short-term symptomatic assistance is needed to address discomfort and tension, supporting improved day-to-day comfort.”


Quick Fact: Relief for Pain and Inflammation


Regulatory References

  1. Diclofenac: NIH StatPearls overview

Eligibility and Restrictions for Use

Eligibility for Dicloced (Diclofenac)

Official regulatory information defines who cannot use Dicloced based on certain pre-existing conditions and physiological states. Use is contraindicated (strictly prohibited) for patients with a known allergy to diclofenac, aspirin, or any other NSAIDs, or a history of allergic-type reactions like aspirin-sensitive asthma.

Contraindications also include established severe heart failure (NYHA Class II-IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease. It must not be used immediately before or after coronary artery bypass graft (CABG) surgery. The drug is also prohibited for patients with active gastrointestinal ulcers, bleeding, or perforation, or a history of these serious events related to prior NSAID use. Severe hepatic (liver) or renal (kidney) failure are also listed as contraindications.

Special Restrictions and Considerations

Population Group Eligibility Status (Regulatory Basis)
Pregnancy (Third Trimester) Contraindicated (Avoid use from 30 weeks gestation)
Children/Adolescents Contraindicated or Not Recommended (Specific age limits apply, typically below 14 or 16 depending on formulation)
Elderly Patients Caution (Increased risk for GI and renal events; use the lowest effective dose)
Recent Heart Attack (MI) Avoid (Unless benefits outweigh the risk of recurrent thrombotic events)

Eligibility is limited to individuals who do not have these specific contraindications and for whom the prescriber has assessed that the benefits outweigh potential risks, especially in cases of cardiovascular risk factors or conditions requiring caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Dicloced (Diclofenac) through several key categories of risk and substance restriction. The primary concern involves pharmacodynamic interactions that increase the risk of bleeding and ulceration. For example, co-administration with anticoagulants, antiplatelet agents, Selective Serotonin Reuptake Inhibitors (SSRIs), or systemic corticosteroids is documented to increase the risk of serious hemorrhage or gastrointestinal damage.

Restrictions and Pharmacokinetic Changes

Interaction Type Interacting Agents (Official Examples) Regulatory Outcome
Exposure Modification Voriconazole, Lithium, Digoxin, Methotrexate Increases plasma concentration/exposure of Diclofenac or the co-administered drug.
Functional Interference ACE Inhibitors, ARBs, Diuretics Officially diminishes the antihypertensive or natriuretic effect and carries a risk of renal function deterioration.
Prohibited Use CABG Surgery, Other Systemic NSAIDs Use is contraindicated in the setting of Coronary Artery Bypass Graft surgery. Co-administration with other systemic NSAIDs is generally advised against.

These interactions necessitate careful consideration, particularly as the risk of renal deterioration with ACE inhibitors and ARBs is heightened in elderly, volume-depleted, or renal-impaired patients. Additionally, the official label notes that alcohol may increase the risk of serious gastrointestinal events.

Mechanism of Action

The compound acts through multiple biochemical pathways, primarily by modulating key enzyme-mediated signaling to influence specific dysregulated physiological signaling patterns. Its mechanistic action involves influence on both local mediator production and central nervous system signaling pathways.


Cyclooxygenase Enzyme Inhibition

This mechanistic domain covers the core function of the drug: inhibiting the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. By competitively binding to the active sites of these enzymes, the compound suppresses the formation of eicosanoids, such as prostaglandins, prostacyclins, and thromboxanes. This cascade modification leads to the resulting physiological effect of altered prostanoid levels and a modulation of afferent nerve signaling activity.


Nociceptive Pathway Modulation

This domain addresses the drug's influence on specific signaling sequences beyond the local site. The compound is suggested to engage the L-arginine nitric oxide-cyclic GMP (cGMP) pathway, which is associated with central and peripheral nociceptive signaling modulation. This engagement influences feedback regulation within the nociceptive pathway, contributing to the regulation of processes driven by distinct signaling patterns.

Dosage and Administration Information

Administration Scope

The medicine, based on its various formulations, is administered through Oral, Topical (e.g., gel, solution), Rectal (suppository), and Parenteral (intravenous/intramuscular) routes. The foundational principle across all uses is to employ the lowest effective dose for the shortest duration consistent with the necessary treatment pattern.


Dosing and Frequency Patterns

For oral administration, dosing schedules vary by formulation and indication. Delayed-Release tablets are typically prescribed in divided doses, such as 50 mg two or three times daily, with daily maximums defined for conditions like Osteoarthritis (150 mg/day) or Rheumatoid Arthritis (up to 200 mg/day). Extended-Release tablets are generally administered once daily at 100 mg. Topical gels and solutions are usually applied two to four times daily, with specific amounts (e.g., 2g or 4g) and maximum daily totals authorized for application to affected joints.


Special Administration Requirements

Specific oral forms, such as the powder for oral solution, must be mixed with water only and consumed on an empty stomach, as food may reduce the efficacy of the immediate-release formulation. In contrast, Delayed- and Extended-Release tablets must be swallowed whole and are not to be crushed or split. Different oral Diclofenac formulations are not bioequivalent and should not be interchanged on a milligram-for-milligram basis. If a regular dose is missed, the instruction is to skip the missed dose and resume the regular schedule, without taking a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dicloced

The information below summarizes the types of clinical studies and research examined the active ingredient in Dicloced, detailing what was examined and what the findings generally reflect.


Evidence for Use in Chronic Joint and Inflammatory Conditions

A significant portion of the evidence for Dicloced was studied for use in conditions characterized by fluctuating or episodic manifestations, such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Research has explored various formulations in intermediate-term Randomized Controlled Trials (RCTs). The main outcomes measured included patient-reported outcomes describing perceived discomfort and changes in daily functioning or activity level.

For the topical gel formulation, studies report how symptoms evolved in the observed populations, and findings describe patterns observed in the trials that reflect a structural difference when compared to the topical carrier (placebo) alone. Research on the oral form was observed in studies monitoring outcomes related to systemic or functional imbalance.

What Remains Uncertain in This Area

Long-term effects are not fully established in controlled trials that extend significantly beyond 12 weeks; follow-up durations were limited. Furthermore, the data for certain groups remain insufficient for joints, besides the knee and hand, meaning that results apply only to the populations studied.


Evidence for Use in Acute Pain and Musculoskeletal Injuries

Dicloced was evaluated in short-term, single-dose RCTs and systematic analyses conducted during periods of increased symptom activity relevant in trials assessing short-term or episodic symptom patterns associated with acute pain from procedures, as well as strains and sprains.

What the Research Examined

These studies research examined outcomes describing episodic or acute changes, such as measuring how quickly a pre-defined level of symptom change was observed and the tracking of rescue medication use. The studies monitored responses over defined time intervals, often over short time intervals following an injury or procedure.


Long-Term Studies and Follow-Up Data

Studies explored the patterns of longer-term use through Real-World Evidence (RWE) observational studies. These RWE studies data show patterns related to use and studies monitored outcomes recorded over up to approximately one year. This evidence contributes to the broader evidence landscape for patient-reported outcomes describing perceived discomfort over longer intervals.

What is Still Uncertain About the Research Evidence

Subgroup findings are uncertain in some areas, as sample sizes were modest for certain specific patient populations or less common indications. Comparative evidence varies across studies, meaning the research describes patterns observed but often lacks direct comparisons against every other potential treatment option.

Key Studies & References

  1. Diclofenac: Uses, Dosage, Mechanism of Action, and Pharmacokinetics (NIH StatPearls)
  2. Diclofenac Sodium: Mechanism of Action and Clinical Application (NIH StatPearls)
  3. NICE Guideline NG226: Osteoarthritis in over 16s: diagnosis and management (Recommendations on NSAIDs)

Frequently Asked Questions (FAQ)

Common questions about Dicloced (FAQ)

Q: Are there any common foods or drinks I should avoid while using Dicloced?

Official product information notes that alcohol consumption may increase the risk of serious gastrointestinal events. Furthermore, regulatory information indicates that specific oral formulations are to be mixed with water only and are generally administered on an empty stomach, as food may affect the absorption of the medicine.

Q: Is Dicloced generally safe for older adults, and are there extra precautions?

Regulatory documents indicate that older adults face a generally higher risk for serious adverse events affecting the stomach, intestines, and kidneys. To help minimize these risks, official regulatory guidance emphasizes the importance of using the lowest effective dose for the shortest duration necessary.

Q: What are the signs that a side effect from Dicloced is serious enough to worry about?

Official warnings describe several serious signs to watch for, including chest pain, shortness of breath, sudden swelling, or unexplained weight gain. Additionally, signs of internal bleeding, such as black or tarry stools or vomiting blood, are critical. Experiencing these symptoms is generally recognized as a signal to consult with a healthcare professional promptly.

Q: Can Dicloced affect my sleep or make me feel restless?

Post-marketing safety reports, which collect information on patient experiences after a drug is released, have occasionally included effects on the nervous system. These documented side effects include trouble sleeping (insomnia), nightmares, and general drowsiness.

Q: What happens if I accidentally miss a dose of Dicloced?

Official instructions typically advise skipping the missed dose if a regular schedule is missed. The regular dosing schedule should be resumed, and taking a double dose to compensate for the one you missed is generally advised against.

Q: Can I use Dicloced if I have a history of kidney stones?

Official warnings caution that Dicloced can cause toxicity in the kidneys and is strictly prohibited in patients with severe kidney failure. A pre-existing kidney condition, such as a history of kidney stones, is generally noted as requiring careful assessment by a healthcare professional.

Q: Is there a maximum number of days or weeks Dicloced should be taken continuously?

Regulatory guidance instructs that the drug should be used for the shortest duration consistent with individual patient treatment goals to minimize risk. There is no single, mandatory maximum duration specified for all patients or all indications.

Q: What is the risk of an allergic reaction to Dicloced, and what does it look like?

Regulatory documents state that signs of a serious, life-threatening allergic reaction may include difficulty breathing, swelling of the face, tongue, or throat, or the sudden appearance of hives. If symptoms of a severe reaction occur, immediate emergency consultation is generally advised.

Q: Is it normal to experience fluid retention or swelling in the ankles with Dicloced?

Official product information notes that fluid retention (edema) and swelling have been observed as side effects in some patients using this medication. It is important for patients to be alert to unexplained weight gain or swelling, particularly in the ankles and feet, as official warnings note this could potentially indicate a cardiovascular issue.

Q: What kind of studies have been done on the long-term safety of Dicloced?

Clinical trials, including those for other similar medicines, have examined cardiovascular risks associated with use up to three years. These studies highlight that the risk of serious events may increase with prolonged use, indicating why duration is an important safety consideration noted in official guidance.

Q: Does Dicloced thin the blood, and what does that mean for me?

The drug is known to interfere with platelet aggregation, which is a key part of the blood clotting process. Because of this anti-platelet effect, regulatory documents state that taking Dicloced alongside other blood-thinning medicines may increase the overall risk of serious bleeding.

Q: Does Dicloced cause sensitivity to the sun or skin reactions?

Serious skin reactions, such as Stevens-Johnson Syndrome, are documented as potential severe side effects. Additionally, some official product labels for topical formulations advise against sunlight exposure in the treated area due to a risk of photosensitivity (increased sun sensitivity).

Q: Does taking Dicloced affect blood sugar levels for someone with diabetes?

Post-marketing safety reports have included rare occurrences of changes in blood sugar levels, specifically high blood sugar (hyperglycemia) and low blood sugar (hypoglycemia). Patients with diabetes are generally advised to monitor blood sugar levels closely during use of this medication.

Q: What is the 'half-life' of Dicloced, and why is that important?

The half-life refers to the time it takes for half of the drug to be eliminated from the bloodstream, which is approximately one to two hours for Dicloced. This measurement is useful for understanding how quickly the drug is processed, though the official labeling notes its therapeutic effects may last longer because it persists in affected areas like joint fluid.

Q: Can Dicloced be used to treat swelling that isn't painful?

The drug's primary mechanism of action involves reducing inflammation. Official labeling indicates the drug is used for the relief of the signs and symptoms of inflammatory conditions, which include swelling. Therefore, its anti-inflammatory property is utilized to address swelling as a component of the conditions it is indicated to treat.

Q: Is it a common side effect of Dicloced to feel anxious or have mood changes?

Changes in mood, including reports of anxiety and psychotic reactions, have been documented in official adverse event reporting. These types of effects are typically classified as less common events reported after the drug has been made available to the public.

How should Dicloced be stored and disposed of?

Diclofenac Storage and Disposal

Storage Requirements

Diclofenac tablets must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), to maintain chemical stability. The container must be kept tightly closed and stored out of the sight and reach of children. The product must be protected from light and moisture and must be kept away from heat and must not freeze.


Disposal Instructions

Unused or expired Diclofenac should be disposed of through a drug take-back program or an authorized collection site. The product is not on the list of medicines approved by the FDA for flushing down the toilet. If a take-back option is unavailable, follow household disposal procedures by mixing the medicine with an undesirable substance, sealing it in a container, and placing it in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dicloced found in:

A-Z Index: